Navigation Links
Pfizer Overtakes GSK but Trails Roche in PharmaDeals' Corp-METRx Analysis of Deal Activity
Date:9/26/2011

OXFORD, England, September 26, 2011 /PRNewswire/ --


PharmaVentures, the experts in deals and alliances, announced today that Corp-METRx, the new definitive analysis on the dealmaking and financial performance of the top 12 pharmaceutical companies, is launched.

The first release of this monthly report on all of the top 12 pharmaceutical companies shows Pfizer has overtaken GlaxoSmithKline and are now placed second only to Roche in the industry's new Deal Activity League Table*. The first monthly edition is available as a free download on our website (http://www.pharmadeals.net/corpmetrx). The ranking  information and expert insight from PharmaVentures will be invaluable to analysts, M&A and corporate finance professionals in investment banks, hedge funds, large cap advisory and asset management firms as well as business development and competitive intelligence professionals, chief executives and other senior managers within pharmaceutical and biotechnology companies."

PharmaDeals® Corp-METRx provides key metrics on the relative strengths and weaknesses of the world's top 12 pharmaceutical companies, and is delivered in a concise and instantly accessible online format. This new publication, edited by PharmaVentures' expert, Nigel Borshell, provides an essential look-up for key facts about how major pharmaceutical companies' deal making activities vary, the impact this has on their peer group ranking and how this evolves with time.

Anne Vindenes Allen, PharmaDeals'  Executive Director, says, "The industry was in need of a report that would readily analyse how well top companies are performing as deal makers, and  PharmaDeals Corp-METRx does just that. Reports on each company are available, along with our expert assessment reviewing the changes of all those 12 companies."

Download the free first edition of PharmaDeals Corp-METRx and read the monthly review article now:

http://www.pharmadeals.net/corpmetrx

Note to Editors

If you wish to write an article, please contact us for any further information you require.

About PharmaDeals Corp-METRx (http://www.pharmadeals.net/corpmetrx)

Key Learnings:

  • Which of the top 12 is the deal making leader for different therapeutic areas.
  • Who is striking the most deals in the short term.
  • How do they rank in terms of their long term deal strategies.
  • Who are the most acquisitive in the M&A sector
  • How are these companies balancing internal and external pipeline filling.

Companies Followed:

  • Abbott Laboratories
  • AstraZeneca
  • Bayer Healthcare
  • Bristol-Myers Squibb
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Novartis
  • Pfizer
  • Roche
  • Sanofi

PharmaVentures (http://www.pharmaventures.com) is an international healthcare advisory group providing leadership in all aspects of deals and alliances, from strategy formulations to implementation. The company occupies a special position in the global marketplace because of our track record of successful outcomes, resulting from our unique insight into the world of deal making, our internationally recognised analytical and valuation capabilities, our own proprietary deal making database PharmaDeals® (http://www.pharmadeals.net),

containing over 40,000 deal records, and our extensive business relationship network and our outstanding success in M&A transactions. Its subsidiary, PharmaTelevision (http://www.pharmatelevision.com) produces the world's first dedicated online pharmaceutical television channel.

Our Services Cover:

Valuation (for licensing, acquisitions, divestments, fund raising & expert testimonies)
Licensing (In and Out licensing)
M&A (Companies & Assets)
Strategy (commercialisation, deal strategy, due diligence, market entry)
Expert Testimony (Patent Infringement, Deal Disagreements, Taxation, Determining Damages)

Now in its 20th year, PharmaVentures is based in Oxford, UK, and employs over 30 people.

*Source: (PharmaDeals Corp-METRx, Pfizer, August 2011, DOI 10.3833/pdcmx.v2011i2.1540).

PharmaDeals® Is a registered Trade Mark of PharmaVentures Ltd.

For further information, contact:
Anne Vindenes Allen
Executive Director, PharmaDeals
+44(0)1865-332700
anne.allen@pharmaventures.com



'/>"/>
SOURCE PharmaVentures Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. QIAGEN and Pfizer Partner to Develop Companion Diagnostic for Novel Compound in Global Clinical Trials for Lung Cancer
2. Pfizer Receives Complete Response Letter from FDA for REMOXY®
3. BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer
4. AFSCME Urges Shareholders to Vote against Executive Compensation at Pfizer (PFE) and Johnson & Johnson (JNJ)
5. BioSpecifics Technologies Corp. Announces Launch of XIAPEX® by Pfizer for Treatment of Dupuytrens Contracture in Europe
6. Former Pfizer Inc. Senior Director Joins Growing MusclePharm Medical Advisory Board
7. Auxilium Pharmaceuticals, Inc. Announces Launch of XIAPEX® in EU by Pfizer
8. Erica L. Mann, Former Pfizer Executive, Appointed New President of Bayer HealthCares Global Consumer Care Division
9. Pfizer Chief Medical Officer Freda Lewis-Hall Named 2011 Woman of the Year by The Healthcare Businesswomens Association
10. Pfizer Animal Health to Acquire Synbiotics Corporation, Entering Diagnostics Sector
11. Pfizer Submits Applications to FDA and EMA for Use of its Pneumococcal Conjugate Vaccine, Prevnar 13®, in Adults 50 and Older
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Dec. 7, 2016 Global Pulmonary ... drugs studies the current as well as future ... this report include companies and intermediaries engaged in ... and/or drug-device combinations as well as new entrants ... an elaborate executive summary along with a market ...
(Date:12/7/2016)... Diplomat Pharmacy, Inc. (NYSE: DPLO) has launched Diplomat Specialty ... IV Infusion Professional, BioRx, MedPro Rx, and XAS Infusion Suites. ... diplomat.is/specialty-infusion .  ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ... "As we continue to build on the work we have ...
(Date:12/7/2016)... ALTO, Calif. , Dec. 7, 2016  Varian ... an update to its previously announced plans to separate ... be executed via a tax-free distribution to Varian stockholders ... stand-alone public company that will hold the Imaging Components ... expected to be executed by the end of January ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Kenall Manufacturing, a leader in sealed healthcare ... The MPCNGX is a multi-function, sealed, LED luminaire that meets the needs of everyone ... when it’s needed. , A 2’ x 4’ model features four modes: ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... a women growing up with a schizophrenic mother in a unique, personal perspective ... who specializes in treating trauma and addictive disorders at her private psychotherapy practice. ...
(Date:12/7/2016)... Valley, CA (PRWEB) , ... December 07, 2016 , ... ... be used in several ways to restore a more youthful appearance to the face. ... now offer Sculptra, along with a variety of other treatments, to rejuvenate and renew ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... When it came time to blow out ... Just 40 minutes later, the Pediatric Heart Transplant team at Joe DiMaggio Children’s ... the Weston teen the hospital’s 30th heart transplant recipient. , “He was playing at ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... planning services to families and business owners in the greater Dallas metropolitan area, ... the Dallas Fallen Officer Foundation. , Established in 2009 by active police professionals ...
Breaking Medicine News(10 mins):